REDHILL BIOPHAR/S (NASDAQ:RDHL) Upgraded by WBB Securities to “Strong-Buy”

Share on StockTwits

REDHILL BIOPHAR/S (NASDAQ:RDHL) was upgraded by equities research analysts at WBB Securities from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday, Marketbeat.com reports. The firm currently has a $17.00 price objective on the biotechnology company’s stock. WBB Securities’ price target would indicate a potential upside of 129.73% from the stock’s previous close.

Several other research analysts also recently weighed in on the company. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Ascendiant Capital Markets set a $23.00 price target on REDHILL BIOPHAR/S and gave the stock a “buy” rating in a research note on Monday, July 8th. Finally, Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $17.75.

REDHILL BIOPHAR/S stock opened at $7.40 on Friday. The business has a 50 day moving average price of $7.05. The stock has a market cap of $145.66 million, a price-to-earnings ratio of -4.35 and a beta of 1.40. REDHILL BIOPHAR/S has a 12-month low of $5.13 and a 12-month high of $11.49. The company has a quick ratio of 3.99, a current ratio of 4.09 and a debt-to-equity ratio of 0.06.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.04. REDHILL BIOPHAR/S had a negative return on equity of 97.62% and a negative net margin of 506.47%. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.98 million. As a group, analysts predict that REDHILL BIOPHAR/S will post -1.3 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of RDHL. Van ECK Associates Corp boosted its position in shares of REDHILL BIOPHAR/S by 42.1% during the 4th quarter. Van ECK Associates Corp now owns 10,787 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 3,195 shares during the last quarter. Geode Capital Management LLC bought a new position in shares of REDHILL BIOPHAR/S during the 4th quarter valued at approximately $73,000. D. E. Shaw & Co. Inc. bought a new position in shares of REDHILL BIOPHAR/S during the 4th quarter valued at approximately $186,000. Sanders Morris Harris LLC bought a new position in shares of REDHILL BIOPHAR/S during the 2nd quarter valued at approximately $330,000. Finally, Menta Capital LLC boosted its position in shares of REDHILL BIOPHAR/S by 9.4% during the 4th quarter. Menta Capital LLC now owns 93,872 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 8,087 shares during the last quarter. Institutional investors and hedge funds own 35.48% of the company’s stock.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Featured Article: Oversold

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

REDHILL BIOPHAR/S  Upgraded by WBB Securities to “Strong-Buy”
REDHILL BIOPHAR/S Upgraded by WBB Securities to “Strong-Buy”
Wells Fargo & Co Raises Microsoft  Price Target to $160.00
Wells Fargo & Co Raises Microsoft Price Target to $160.00
Johnson & Johnson  Receives New Coverage from Analysts at Credit Suisse Group
Johnson & Johnson Receives New Coverage from Analysts at Credit Suisse Group
Roth Capital Reaffirms “Neutral” Rating for Himax Technologies
Roth Capital Reaffirms “Neutral” Rating for Himax Technologies
Jefferies Financial Group Reaffirms Hold Rating for Healthcare Services Group
Jefferies Financial Group Reaffirms Hold Rating for Healthcare Services Group
Clarus  Now Covered by Macquarie
Clarus Now Covered by Macquarie


© 2006-2019 Ticker Report